FDA grants Priority Review with target action date of June 28, 2024 Application based on results from Phase 1/2 EPCORE™ NHL-1 trial demonstrating clinically meaningful treatment responses in difficult-to-treat patients with relapsed or refractory (R/R) follicular lymphoma (FL) sBLA submission demonstrates Genmab’s commitment to exploring potential utility of epcoritamab across B-cell malignancies COPENHAGEN, Denmark / Feb... Read More